Prev:Next:

Vice director of the national clinical research center for neurological diseases.

Deputy secretary of party committee and executive vice president of Beijing Tiantan Hospital. Director of the quality control center of neurology department in National Health and Family planning commission, director of stroke institute of Beijing major brain disease institute, Executive vice president of Chinese stroke society, the designated chairman of the neurology branch of Chinese medical association, chief editor of the Stroke and Vascular Neurology magazine and chief editor of the China Stroke Magazine. Dr. Wang has worked on the classification and standardized of prevention and control strategies of cerebrovascular diseases based on the pathologies and pathogenesis of stroke.

As one of the chief scientists working for the "12th five-year plan", "13th five-year planned other major research/development plan in regard to cerebrovascular disease, he has accomplished several systematic and innovative research achievements in the critical issue involving diagnosis, treatment and standardized prevention of high-risk non-disabling cerebrovascular disease. The achievements had been widely accepted and used in clinical practice. He has published over 190 papers in several top clinical journals including the NEJM, JAMA, Circulation. The papers have been widely concerned and highly evaluated by Chinese and international peer scientists. He has been nominated as several titles, including "Beijing scholar", "ten thousand people plan" science and technology innovation leading talent and "Beijing High-level innovating and entrepreneurial talent support program outstanding talent”. He won the second prize of National Science and Technology Progress Award, the first prize of Science and Technology Progress of the Ministry of Education, the first prize of Beijing science progress, and first prize of the science of Chinese preventive medicine association, the first prize of technology, national excellent science and technology workers and other awards. His research team won the title of the first batch of excellent innovation team in critical research fields of the Ministry of Science and Technology.

Prof. Yongjun Wang is the primary investigator in the National Platform for the Development of Major New Drugs for Neurological Disease in the 11th/12th/13th Five-Year" National Science and Technology Support Programme. He has completed more than 50 multicenter clinical trials (Stage II/III), including international RCTs, such as the SAINT trial，the FASTEST trial, the ENOS trial, the ATACH II trial, the Navigate-ESUS, trial the Respect ESUS trial, the Socrates trial, the Thales trial and so on. Prof. Yongjun Wang is also an international Steering Committee member in the the Socrates trial and the Thales trial. More than 90 percent of the staffs in the Clinical Trial Center have GCP certifications and are well trained. Prof. Yongjun Wang has designed and completed several investigator-initiated clinical trials, for example the CHANCE trial, which has been adopted by US/European and Chinese guidelines. Prof. Yongjun Wang is also a consultant for Guidelines for pharmaceutical clinical trials for acute ischemic stroke by CFDA. For Stage I clinical trials, advanced technologies such as cerebrospinal fluid collection, isotope tracing, functional imaging, and neuro-electro-physiological assessments will be used to facilitate the new drug research and development.